MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded to “Outperform” at Wolfe Research

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) was upgraded by equities researchers at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Monday, Marketbeat.com reports. The brokerage currently has a $61.00 price target on the stock. Wolfe Research’s price target points to a potential upside of 51.44% from […]

Leave a Reply

Your email address will not be published.

Previous post JMP Securities Raises HCI Group (NYSE:HCI) Price Target to $225.00
Next post Patterson-UTI Energy’s (PTEN) Neutral Rating Reaffirmed at Citigroup